• New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2023 Hybrid Congress
• $350 million in gross proceeds raised in a registered direct offering
• $212 million in gross proceeds raised from private placements
• Gross proceeds of $200 million received from the exercise of warrant issued in May 2021
• Strategic advisory board established with the appointments of John Maraganore, Ph.D., former CEO of Alnylam Pharmaceuticals and Michel Vounatsos, former CEO of Biogen Inc. as advisors
• Mythili Koneru, M.D., Ph.D. appointed as Company’s Chief Medical Officer

SOMERSET, N.J.— MAY 18, 2023 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.

“We are extremely pleased to announce that we have recently raised $762 million in funding. With this substantial capital infusion, we are poised to embark on a critical chapter in our company’s growth to advance CARVYKTI® toward its full potential, and we look forward to presenting the latest data from our CARTITUDE clinical development programs at ASCO and EHA this June,” said Ying Huang, Chief Executive Officer of Legend Biotech. Dr. Huang continued, “We would like to extend our deepest gratitude to our investors for their overwhelming support and confidence in our company’s mission and remain committed to creating long-term value for all of our stakeholders.”

Financial Results for Quarter Ended March 31, 2023

Cash and Cash Equivalents, Time Deposits, and Short-Term Investments

As of March 31, 2023, prior to giving effect to the registered direct offering, private placements or warrant exercise noted above, Legend Biotech had approximately $854 million of cash and cash equivalents, time deposits, and short-term investments.

Revenue

Total revenue for the three months ended March 31, 2023 was $36.3 million compared to $50.0 million for the three months ended March 31, 2022.  Collaboration revenue recognized in the first quarter of 2023 was from CARVYKTI® sales primarily in the U.S. License revenue recognized in first quarter of 2022 was due to the achievement of commercial milestone for FDA approval in the U.S. in connection with the license and collaboration agreement (the “Janssen Agreement”) with Janssen Biotech, Inc. (“Janssen”).

Collaboration cost of revenue

Collaboration cost of revenue for the three months ended March 31, 2023 was $35.6 million. Legend Biotech did not have any collaboration cost of revenue in the three months ended March 31, 2022. The $35.6 million is a combination of Legend’s portion of collaboration cost of sales in connection with collaboration revenue under the Janssen Agreement along with expenditures to support the manufacturing capacity expansion which cannot be capitalized.

Research and Development Expenses

Research and development expenses for the three months ended March 31, 2023 were $84.9 million compared to $81.5 million for the three months ended March 31, 2022.  This increase of $3.4 million was primarily due to higher patient enrollment for Phase 3 clinical trials for cilta-cel in the first quarter of 2023.

Administrative Expenses

Administrative expenses for the three months ended March 31, 2023 were $22.2 million compared to $12.7 million for the three months ended March 31, 2022. The increase of $9.5 million was primarily due to continued investment in building global information technology infrastructure along with non-recurring financial and legal fees related to Legend Biotech’s restatement of its historical financial statements as reported by Legend Biotech in February 2023.

Selling and Distribution Expenses

Selling and distribution expenses for the three months ended March 31, 2023 were $18.0 million compared to $21.3 million for the year three months ended March 31, 2022. This decrease of $3.3 million was primarily due to non-recurring launch expenses incurred in the first quarter of 2022 to support the commercialization in the U.S market.

Other Income and Gains

Other income and gains for the three months ended March 31, 2023 were $8.2 million compared to $1.0 million for the three months ended March 31, 2022. The increase of $7.2 million was primarily due to increase in interest income and gain on investments.

Other Expenses

Other expenses for the three months ended March 31, 2023 were $10.7 million compared to $1.5 million for the three months ended March 31, 2022. The increase was primarily due to unrealized foreign currency exchange loss in the quarter.

Finance Costs

Finance costs for the three months ended March 31, 2023 were $5.1 million compared to $1.0 million for the three months ended March 31, 2022. The increase was primarily due to interest on advance funding, which is interest-bearing borrowings funded by Janssen under the Janssen Agreement and constituted by principal and applicable interests upon such principal.

Fair Value Gain of Warrant Liability

Fair value gain of warrant liability for the three months ended March 31, 2023 was $20.0 million caused by changes in the fair value of a warrant that Legend Biotech issued to an institutional investor through a private placement transaction in May 2021 with an initial fair value of $81.7 million at the issuance date. The warrant was assessed as a financial liability with a fair value of $47.0 million as of March 31, 2023. On May 12, 2023, Legend Biotech announced that the warrant had been exercised in full.

Loss for the Period

For the three months ended March 31, 2023, net loss was $112.1 million, or $0.34 per share, compared to a net loss of $32.3 million, or $0.10 per share, for the three months ended March 31, 2022.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.  

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI^®, including Legend Biotech’s expectations for CARVYKTI^®, such as Legend Biotech’s manufacturing and commercialization expectations for CARVYKTI^® and the potential effect of treatment with CARVYKTI^®; statements about submissions for CARVYKTI^® and other product candidates to, and the progress of such submissions with, the U.S. Food and Drug Administration (FDA) and other regulatory authorities; the anticipated timing of, and ability to progress, clinical trials; the ability to generate, analyze and present data from clinical trials; expected results of clinical trials; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 29, 2023. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

		Three months ended March 31, 2023		Three months ended March 31, 2022
		US$’000, except per share data		US$’000, except per share data
		(Unaudited)		(Unaudited)
REVENUE
License revenue		—		50,000
Collaboration revenue		36,280		—
Other revenue		56		40
Total revenue		36,336		50,040
Collaboration cost of revenue		(35,613)		—
Other income and gains		8,199		1,012
Research and development expenses		(84,889)		(81,548)
Administrative expenses		(22,205)		(12,657)
Selling and distribution expenses		(17,954)		(21,302)
Other expenses		(10,734)		(1,527)
Fair value gain of warrant liability		20,000		34,900
Finance costs		(5,113)		(1,044)
LOSS BEFORE TAX		(111,973)		(32,126)
Income tax (expense)/credit		(128)		(163)
LOSS FOR THE PERIOD		(112,101)		(32,289)
Attributable to:
Ordinary equity holders of the parent		(112,101)		(32,289)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
Basic		(0.34)		(0.10)
Diluted		(0.34)		(0.10)
ORDINARY SHARES USED IN LOSS PER SHARE COMPUTATION
Basic		330,497,072		308,699,034
Diluted		330,497,072		308,699,034

		March 31, 2023		December 31, 2022
		US$’000		US$’000
		(Unaudited)		(Audited)
NON-CURRENT ASSETS
Property, plant and equipment		110,045		105,168
Advance payments for property, plant and equipment		2,193		914
Right-of-use assets		80,459		55,590
Time deposits		4,366		—
Intangible assets		2,289		3,409
Collaboration prepaid leases		93,548		65,276
Other non-current assets		1,062		1,487
Total non-current assets		293,962		231,844
CURRENT ASSETS
Collaboration inventories		12,176		10,354
Trade receivables		56		90
Prepayments, other receivables and other assets		51,761		61,755
Financial assets at fair value through profit or loss		185,705		185,603
Pledged deposits		1,283		1,270
Time deposits		4,366		54,016
Cash and cash equivalents		660,050		786,031
Total current assets		915,397		1,099,119
Total assets		1,209,359		1,330,963
CURRENT LIABILITIES
Trade payables		29,811		32,893
Other payables and accruals		146,378		184,109
Government grants		457		451
Lease liabilities		4,595		3,563
Tax payable		9,940		9,772
Warrant liability		47,000		67,000
Total current liabilities		238,181		297,788
NON-CURRENT LIABILITIES
Collaboration interest-bearing advanced funding		265,864		260,932
Lease liabilities long term		44,302		20,039
Government grants		7,631		7,659
Other non-current liabilities		224		233
Total non-current liabilities		318,021		288,863
Total liabilities		556,202		586,651
EQUITY
Share capital		33		33
Reserves		653,124		744,279
Total ordinary shareholders’ equity		653,157		744,312
Total equity		653,157		744,312
Total liabilities and equity		1,209,359		1,330,963

		Three months ended March 31, 2023		Three months ended March 31, 2022
		US$’000		US$’000
		(Unaudited)		(Unaudited)
LOSS BEFORE TAX		(111,973)		(32,126)
CASH FLOWS USED IN OPERATING ACTIVITIES		(141,053)		(78,687)
CASH FLOWS USED IN INVESTING ACTIVITIES		17,930		(232,500)
CASH FLOWS FROM FINANCING ACTIVITIES		(286)		25
NET DECREASE IN CASH AND CASH EQUIVALENTS		(123,409)		(311,162)
Effect of foreign exchange rate changes, net		(2,572)		10
Cash and cash equivalents at beginning of the period		786,031		688,938
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD		660,050		377,786
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		670,065		667,465
Less: Pledged deposits		1,283		1,448
Time deposits		8,732		288,231
Cash and cash equivalents as stated in the statement of financial position		660,050		377,786
Cash and cash equivalents as stated in the statement of cash flows		660,050		377,786